ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)

Lu, Shun*; Cheng, Ying; Zhou, Jianying; Wang, Mengzhao; Zhao, Jun; Wang, Baocheng; Chen, Gongyan; Feng, Jifeng; Ma, Zhiyong; Wu, Lin; Wang, Changli; Ma, Kewei; Zhang, Shucai; Liang, Jun; Song, Yong; Wang, Jie; Wu, Yi-Long; Li, Ang; Huang, Yizhi; Chang, Jianhua复旦大学; 广东省人民医院; 北京大学; 吉林大学; 上海交通大学; 哈尔滨医科大学; 浙江大学; 郑州大学; 中国医学科学院; 中国医学科学院北京协和医院; 1
Therapeutic Advances in Medical Oncology2022-11DOI: 10.1177/17588359221138380
2被引26阅读
引用收藏
分享

摘要

Background: Nivolumab has been approved in China as second-line treatment for advanced non-small-cell lung cancer (NSCLC) via weight-based infusion, based on the CheckMate 078 study. We investigated the safety and efficacy of 240 mg flat-dose nivolumab in patients with advanced NSCLC, including those with hepatitis B virus (HBV) and epidermal growth factor receptor (EGFR) mutation/ALK receptor tyrosine kinase (ALK) translocation due to high prevalence in China. @@@ Methods: CheckMate 870 was a single-arm, open-label, phase IIIb trial in Asian (primarily Chinese) patients with previously treated advanced NSCLC. Patients received flat-dose nivolumab 240 mg every 2 weeks (Q2W) for up to 2 years. The primary endpoint was the incidence and severity of treatment-related select adverse events (TRsAEs) in non-HBV patients; secondary and exploratory endpoints included severity of high-grade TRsAEs in HBV-infected patients, and safety, efficacy and patient-reported outcomes (PROs) in the whole population. @@@ Results: Out of 404 patients enrolled, 400 received treatment. Median (standard deviation) age was 60.5 (8.68) years and the majority were male (78.5%). At a median follow-up of 37.6 months, no Grade 5 TRsAEs were reported, and the frequency of Grade 3-4 TRsAEs was low (0.0-5.9%) in non-HBV and HBV NSCLC patients. Median overall survival (OS) and progression-free survival (PFS) in all treated patients were 14.7 (12.3-18.1) and 3.6 (2.3-3.8) months, respectively. Median OS was 14.2 (12.3-18.1) and 22.3 (10.0-NA) months for non-HBV and HBV-infected patients, 19.3 (11.2-31.7) and 13.7 (11.5-18.1) months for EGFR-positive and wild-type subgroups, and 19.3 (12.9-23.5) and 13.3 (10.9-17.7) months for those with programmed death-ligand 1 (PD-L1) expression.1% and <1%, respectively. No notable changes from baseline were observed in PROs throughout the study. @@@ Conclusion: Nivolumab 240 mg infusion Q2W was well tolerated, efficacious, and maintained health status and quality of life in Asian patients with previously treated advanced NSCLC regardless of HBV, EGFR, or PD-L1 status.

学科与关键词

关键词
ChineseEGFR mutationflat dosinghepatitis BNivolumabNSCLC
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Medical Oncology
发表日期
2022-11
卷期
第 14 卷
DOI
10.1177/17588359221138380
语言
ENGLISH
期刊等级
2区
成果收录
SCIE

作者

  • L

    Lu, Shun (通讯) (第一作者)

    shanghai jiao tong univ

  • C

    Cheng, Ying

查看全部 20 位作者收起作者
  • Z

    Zhou, Jianying

    1 · zhejiang univ

  • W

    Wang, Mengzhao

    peking union med coll hosp

  • Z

    Zhao, Jun

  • W

    Wang, Baocheng

    jinan mil gen hosp

  • C

    Chen, Gongyan

    harbin med univ

  • F

    Feng, Jifeng

    jiangsu inst canc res · nanjing med univ

  • M

    Ma, Zhiyong

    zhengzhou univ

  • W

    Wu, Lin

    hunan canc hosp

  • W

    Wang, Changli

    tianjin med univ

  • M

    Ma, Kewei

    1 · jilin univ

  • Z

    Zhang, Shucai

    beijing chest hosp

  • L

    Liang, Jun

    peking univ

  • S

    Song, Yong

    nanjing gen hosp

  • W

    Wang, Jie

    chinese acad med sci

  • W

    Wu, Yi-Long

    guangdong prov peoples hosp

  • L

    Li, Ang

  • H

    Huang, Yizhi

  • C

    Chang, Jianhua

    fudan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417